Q3 2023

Filed Nov 13, 2023 · 10-Q · 44 days after period end · 0001477932-23-008286

Q3 2023 · 10-Q

Revenue

$0.00

−100.0% vs Q3 2022

Net Income

-$677.00K

N/M vs Q3 2022

EPS Diluted

-$0.01

N/M vs Q3 2022

Gross Profit-$4,000N/M

Operating Income

Same quarter

Metric	Q3 2023	Q3 2022	Q3 2021	Q3 2020
Revenue	$0.00	$3.00K	$19.00K	$77.00K
Net Income	-$677.00K	$1.10M	$68.00K	$1.58M
EPS Diluted	-$0.01	-$0.03	$0.00	$0.03

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR